CORRECTION



Correction to: Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy

Xiang-Dong Li, MD^{1,2}, Chao-Wen Huang, MD^{1,2}, Ze-Fu Liu, MD^{1,2}, Li-Juan Jiang, MD^{1,2}, Jie-Wei Chen, MD^{1,3}, Dan Xie, MD, PhD^{1,3}, Fang-Jian Zhou, MD, PhD^{1,2}, Hui-Ming Lu, MD^{1,2}, and Zhuo-Wei Liu, MD, PhD^{1,2}

¹State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China; ²Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; ³Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China

CORRECTION TO: ANN SURG ONCOL HTTPS://DOI.ORG/10.1245/S10434-019-07529-Y

In the original article, the word IMMUNOSCORE[®] was not displayed to reflect its trademark status. At every mention, IMMUNOSCORE[®] should be in all caps and with a registered trademark symbol.

The following sentence is missing in the "Methods" section and is published here to correct this oversight: IMMUNOSCORE[®] is a registered trademark owned by INSERM.

The original article can be found online at https://doi.org/10.1245/ s10434-019-07529-y.

© Society of Surgical Oncology 2019

Published Online: 22 November 2019

H.-M. Lu, MD e-mail: luhm@sysucc.org.cn

Z.-W. Liu, MD, PhD e-mail: liuzhw@sysucc.org.cn